Additional Relevant Details Celgene was notified that Actavis LLC (acquired Allergen in early 2015 and adopted the Allergen corporate name) had filed an Abbreviated New Drug Application to the FDA for the manufacturing and marketing of a generic Abraxane.  Celgene plans to "vigorously defend its extensive intellectual property rights relating to Abraxane".  Abraxane is indicated for the treatment of different types of cancer, including breast cancer and small-cell lung cancer.